Progress on US sales will be key for further Torrent Pharma's stock gains
Lower copra costs and price cuts to aid volumes and margins
Inability to pass on the entire cost will squeeze margins
At the current price, the stock is trading at 30x its FY23 earnings estimates
Higher exports may offset some of the volume, cost pressure
Buyback could support the price in the near term
US price erosion, India growth trends would be keenly tracked
Rental renegotiations another dampener for the stock
Price hikes to pass on the costs will be difficult amid falling volumes
Brokerages are however positive on medium term growth outlook for core and new areas
They advise investors to focus on quality companies as they list their favourite picks
Focus on backward integration and value addition to help on the margin front
Supply of Molnupiravir to Merck was a key near-term trigger for the stock
Aggressive expansion and good execution are expected to could keep growth rates elevated going ahead
Public sector banks, information technology companies, cement makers, and consumption plays are among other picks
Sharp run in stock prices over the past three months, however, caps near term upside
Despite rising debt, margin pressures, the company has maintained its FY22 guidance
Valuations, however, cap upsides in the near term
Decision by the panel on tobacco tax remains the key trigger
Cost pressures to sustain as company is committed to increasing advertising spends